ADRB3 and fetal growth restriction: In IUGR-born neonatal sheep, daily oral administration of the Adrβ2 agonist clenbuterol together with the Adrβ1 antagonist atenolol and the Adrβ3 antagonist SR59230A from birth to 30 days of age improved peripheral tissue insulin sensitivity and enhanced glucose utilization rates (Yates et al., 2019).